Marizomib for patients with newly diagnosed glioblastoma: a randomized phase 3 trial.
Patrick RothThierry GorliaJaap C ReijneveldFilip de VosAhmed IdbaïhJean-Sébastien FrenelEmilie Le RhunJuan Manuel SepulvedaJames PerryG Laura MasucciPierre FreresHal HirteClemens SeidelAnnemiek WalenkampSlavka LukacovaPaul MeijndersAndre BlaisFrancois DucrayVincent VerschaeveGarth NicholasCarmen Balaña QuinteroDaniela A BotaMatthias PreusserSarah NuyensFréderic DhermainMartin van den BentChris J O'CallaghanMaureen VanlanckerWarren MasonMichael Wellernull nullPublished in: Neuro-oncology (2024)
Adding marizomib to standard temozolomide-based radiochemotherapy resulted in more toxicity, but did not improve OS or PFS in patients with newly diagnosed glioblastoma.